Inherent Risks Associated With Manufacture of Bioengineered Ocular Surface Tissue
Authors:
- Ivan R. SchwabISIvan R. Schwab
- Nigel T. JohnsonNJNigel T. Johnson
- Damien G. HarkinDHDamien G. Harkin
Open Access
- 1 December 2006
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 124 (12) , 1734-1740
Abstract
Advances in bioengineering and stem cell research betoken revolutionary changes in the practice of medicine, but while the science, ethics, and morality have been passionately debated, little attention has been given to managing risks inherent to production protocols, which are often complex and research based. Current investigational protocols rely on the use of animal and/or donor human tissue products and thus carry the potential to induce xenogenic microchimerism in recipients or disease transmission through contamination with bacteria, viruses, or other infectious agents, such as those responsible for transmissible spongiform encephalopathy (TSE).1-5 Until specific guidance can be established for emerging cell-based therapies, potential manufacturers are being encouraged by regulators to adopt strategies that minimize risk to patient well-being. The financial costs of adopting these measures and varying degrees of legislative and regulatory oversight globally may drive future clinical trials to markets with fewer legislative and regulatory restrictions. This is disadvantageous to clinical investigators and may permit the emergence of significant risks to public health on a global scale. This current work examines features of current techniques that may infringe benefits to society.Keywords
This publication has 41 references indexed in Scilit:
- Probability of Viremia with HBV, HCV, HIV, and HTLV among Tissue Donors in the United StatesNew England Journal of Medicine, 2004
- Creutzfeldt-Jakob Disease Following Corneal TransplantationCornea, 2004
- AUTOLOGOUS FIBRIN-CULTURED LIMBAL STEM CELLS PERMANENTLY RESTORE THE CORNEAL SURFACE OF PATIENTS WITH TOTAL LIMBAL STEM CELL DEFICIENCY1Transplantation, 2001
- Reconstruction of Damaged Corneas by Transplantation of Autologous Limbal Epithelial CellsNew England Journal of Medicine, 2000
- Successful Transplantation of Bioengineered Tissue Replacements in Patients with Ocular Surface DiseaseCornea, 2000
- Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epitheliumThe Lancet, 1997
- Allogeneic Fibroblasts Used to Grow Cultured Epidermal Autografts Persist in Vivo and Sensitize the Graft Recipient for Accelerated Second-Set RejectionThe Journal of Trauma: Injury, Infection, and Critical Care, 1996
- HIV-1 Spreads from Lymphocytes to Normal Human Keratinocytes Suitable for Autologous and Allogenic TransplantationJournal of Investigative Dermatology, 1995
- Differentiation-related expression of a major 64K corneal keratin in vivo and in culture suggests limbal location of corneal epithelial stem cells.Journal of Cell Biology, 1986
- QUANTITATIVE STUDIES OF THE GROWTH OF MOUSE EMBRYO CELLS IN CULTURE AND THEIR DEVELOPMENT INTO ESTABLISHED LINESJournal of Cell Biology, 1963